Predicting Complications in Women With Toxaemia
Information source: University of British Columbia
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Toxemia
Intervention: preeclampsia (Behavioral)
Phase: N/A
Status: Active, not recruiting
Sponsored by: University of British Columbia Official(s) and/or principal investigator(s): Peter von Dadelszen, MD, Principal Investigator, Affiliation: University of British Columbia
Summary
At present, the management of pre-eclampsia is guided by expert opinions that are not
well-based on firm evidence. What is required is a clinical tool that can accurately
determine a women's risk for adverse outcomes, and thereby reduce the risk for women while
safely prolonging pregnancies remote from term (to improve fetal outcomes). This research
project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is
specific to the condition. This severity score will be used clinically (to guide management)
and in research (in both clinical trials and basic science research), and will provide an
evidence base on which to build future practice, improving outcomes for pregnant women and
their babies. In addition, this project is part of a three part strategy to better
understand the mechanisms of disease in pre-eclampsia and to investigate a potential
disease-modifying therapy, namely, recombinant human activated protein C.
Clinical Details
Official title: PIERS (Pre-eclampsia Integrated Estimate of RiSk) Model: Predicting Adverse Maternal Outcomes in Pre-eclampsia
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: To identify the maternal and fetal variables predictive of a combined adverse maternal outcome occurring within one week of hospital admission for pre-eclampsia
Secondary outcome: To identify whether these also predict the combined adverse maternal outcome at any time following admission ii to identify whether these variables can predict a combined adverse perinatal outcome both (a) within one week and (b) at any time foll
Detailed description:
In North America, pre-eclampsia ('toxaemia of pregnancy') is the most common cause for women
to die during or shortly after pregnancy. It is also the most common reason for babies who
are otherwise doing well to be delivered prematurely; this is with the intent purpose of
protecting maternal health and safety. In many ways it is similar to the systemic
inflammatory response syndrome ('septicaemia').
This project is part of a three part strategy to better understand the mechanisms of disease
in pre-eclampsia and to investigate a potential disease-modifying therapy, namely,
recombinant human activated protein C. We have surveyed Canadian practice, and undertaken
both feasibility and pilot studies for this project.
At present, the management of pre-eclampsia is guided by expert opinions that are not
well-based on firm evidence. What is required is a clinical tool that can accurately
determine a women's risk for adverse outcomes, and thereby reduce the risk for women while
safely prolonging pregnancies remote from term (to improve fetal outcomes). This research
project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is
specific to the condition. To develop and validate the tool we will recruit 3000 women in
Canada, the UK, and Australasia who are admitted to a hospital with either pre-eclampsia or
one of its variants. At the same time, because the majority of deaths associated with
pre-eclampsia occur in low and middle income countries, we will recruit 3000 women from
Uganda, China, Fiji, South Africa and Pakistan with pre-eclampsia. We will use this cohort
to test the model and ensure it accurately predicts risk in this new population.
This severity score will be used clinically (to guide management) and in research (in both
clinical trials and basic science research), and will provide an evidence base on which to
build future practice, improving outcomes for pregnant women and their babies.
Eligibility
Minimum age: 16 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
These criteria reflect the evidence that pre-eclampsia is more than hypertension and
proteinuria, particularly at onset:
- Hypertension. sBP >140mmHg and/or dBP >90mmHg, twice, >4h apart after 20 weeks'
gestation. sBP will be included to reflect international guidelines.
- Proteinuria. 24h urinary protein >0. 3g/d3, or in the absence of a 24h urine
collection: >2+ dipstick proteinuria after 20wk or a random protein: creatinine ratio
>30mg protein/mmol creatinine106-108.
- HELLP syndrome that is non-hypertensive and non-proteinuric, using Sibai's
criteria109,
- One eclamptic seizure without preceding hypertension or proteinuria ('BEST'
definition of eclampsia38).
- Women admitted with suspected 'superimposed pre-eclampsia' will also be included
(e. g., those with a history of pre-existing hypertension with new proteinuria (>2+)
or accelerated hypertension3;23;24).
Exclusion Criteria:
- Occurrence of the maternal outcome (e. g., recurrent eclampsia) prior to collection of
the predictors.
- Admission to hospital in spontaneous labour (as clinicians will not attempt to stop
these labours).
Locations and Contacts
Christchurch Women's Hospital, Christchurch, New Zealand
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Children's and Women's Health Centre of BC, Vancouver, British Columbia V5Z 1L8, Canada
Kingston General Hospital, Kingston, Ontario, Canada
Ottawa Hospital-General Campus, Ottawa, Ontario, Canada
le Centre hospitalier universitaire de Sherbrooke, Sherbrook, Quebec, Canada
Additional Information
Starting date: September 2005
Last updated: April 10, 2015
|